Client CAMP4 Therapeutics Enters Research Collaboration with BioMarin Pharmaceutical to Develop RNA-Targeting Medicines for Genetic Diseases

In The News
October 3, 2024

Ropes & Gray advised CAMP4 Therapeutics in a research collaboration with BioMarin Pharmaceutical aimed at advancing novel therapeutics that increase protein levels by targeting regulatory RNA sequences, which are key in controlling gene expression. The collaboration was announced on October 1.

Under the agreement, BioMarin will select two targets identified through CAMP4’s RAP Platform for development. CAMP4 will receive an upfront payment and is eligible for additional milestone payments and tiered royalties based on collaboration success. The collaboration allows CAMP4 to expand its platform to additional therapeutic targets and strengthens BioMarin’s position in genetic medicines.

The Ropes & Gray team included life sciences licensing partner Hannah England and life sciences licensing associate Ian Nilsen.